XML 20 R5.htm IDEA: XBRL DOCUMENT v3.20.4
Statements of Stockholders' Equity - USD ($)
Total
Series D Convertible Preferred Stock
Series E Convertible Preferred Stock
Preferred Stock
Preferred Stock
Series D Convertible Preferred Stock
Preferred Stock
Series E Convertible Preferred Stock
Common Stock
Common Stock
Series D Convertible Preferred Stock
Common Stock
Series E Convertible Preferred Stock
Additional Paid-In Capital
Additional Paid-In Capital
Series D Convertible Preferred Stock
Additional Paid-In Capital
Series E Convertible Preferred Stock
Service Receivable
Accumulated Deficit
Accumulated Deficit
Series D Convertible Preferred Stock
Accumulated Deficit
Series E Convertible Preferred Stock
Balance (in shares) at Dec. 31, 2018       60,600     3,831,879                  
Balance at Dec. 31, 2018 $ 10,084,192     $ 60     $ 7,742     $ 202,267,605     $ 0 $ (192,191,215)    
Increase (Decrease) in Stockholders' Equity                                
Sale of common stock and warrants, net of expenses (in shares)             1,994,929                  
Sale of common stock and warrants, net of expenses 8,817,772           $ 199     8,817,573            
Issuance of common stock, preferred stock and warrants for clinical trial funding commitment, net of expenses and discount (in shares)       200,000     183,334                  
Issuance of common stock, preferred stock and warrants for clinical trial funding commitment, net of expenses and discount (40,000)     $ 200     $ 110     1,634,690     (1,675,000)      
Stock-based compensation 884,942                 884,942            
Issuance of common stock upon exercise of warrants (in shares)             2,221,635                  
Issuance of common stock upon exercise of warrants 3,299,510           $ 223     3,299,287            
Issuance of common stock upon vesting of restricted stock awards (in shares)             22,057                  
Issuance of common stock upon vesting of restricted stock awards 0           $ 5     (5)            
Deemed dividend recognized on beneficial conversion features of Series C Convertible Preferred Stock issuance 0                 268,269       (268,269)    
Issuance of common stock upon conversion of Convertible Preferred Stock (in shares)       (200,000)     333,333                  
Issuance of common stock upon conversion of Convertible Preferred Stock 0     $ (200)     $ 33     167            
Preferred stock dividend payable on Series A Convertible Preferred Stock (24,240)                         (24,240)    
Issuance of common stock for share rounding as a result of reverse stock split (in shares)             6,466                  
Release of clinical trial funding commitment 703,327                       703,327      
Net loss (16,414,159)                         (16,414,159)    
Balance (in shares) at Dec. 31, 2019       60,600     8,593,633                  
Balance at Dec. 31, 2019 7,311,344     $ 60     $ 8,312     217,172,528     (971,673) (208,897,883)    
Increase (Decrease) in Stockholders' Equity                                
Issuance of common stock, preferred stock and warrants for clinical trial funding commitment, net of expenses and discount (in shares)       154,670     602,833                  
Issuance of common stock, preferred stock and warrants for clinical trial funding commitment, net of expenses and discount (7,500)     $ 15     $ 60     2,292,425     (2,300,000)      
Stock-based compensation 1,764,804                 1,764,804            
Issuance of common stock upon exercise of warrants (in shares)             12,138,469                  
Issuance of common stock upon exercise of warrants 24,871,586           $ 1,214     24,870,372            
Issuance of common stock upon vesting of restricted stock awards (in shares)             10,810                  
Issuance of common stock upon vesting of restricted stock awards 0           $ 1     (1)            
Deemed dividend recognized on beneficial conversion features of Series C Convertible Preferred Stock issuance   $ 0 $ 0               $ 601,767 $ 2,664,717     $ (601,767) $ (2,664,717)
Issuance of common stock upon conversion of Convertible Preferred Stock (in shares)         (154,670) (210,780)   1,546,700 863,852              
Issuance of common stock upon conversion of Convertible Preferred Stock   $ 0 $ 0   $ (15) $ (210)   $ 155 $ 86   $ (140) $ 124        
Preferred stock dividend payable on Series A Convertible Preferred Stock (24,240)                         (24,240)    
Release of clinical trial funding commitment 1,100,415                       1,100,415      
Net loss (19,306,672)                         (19,306,672)    
Sale of stock, shares issued (in shares) [1]       865,824     12,964,313                  
Net proceeds [1] 112,299,949     $ 866     $ 1,297     112,297,786            
Common Stock par value adjustment 0           $ (7,453)     7,453            
Issuance of common stock upon exercise of stock options (in shares)             60,195                  
Issuance of common stock upon exercise of stock options 148,196           $ 6     148,190            
Balance (in shares) at Dec. 31, 2020       715,644     36,780,805                  
Balance at Dec. 31, 2020 $ 128,157,882     $ 716     $ 3,678     $ 361,820,025     $ (2,171,258) $ (231,495,279)    
[1] Net of expenses of $7,507,123, and fair value of warrants issued as a transaction advisory fee as of the date of issuance of $370,666